✓
Open
9 Jul 2025
✓
Close
11 Jul 2025
3
Allotment
—
✓
Listing
Wed, Jul 16, 2025
Price Band
₹115 to ₹123
Issue Size
22,41,000 shares (agg. up to ₹28 Cr)
Lot Size
1,000 Shares
Listing Date
Wed, Jul 16, 2025
Latest GMP
₹26
Est. Gain
21.14%
✦ AI Insight
GMP Trend
16-07-2025₹26Est. ₹149+21.14%
15-07-2025₹26Est. ₹149+21.14%
14-07-2025₹25Est. ₹148+20.33%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 130.28x |
Restated Financials (₹ Cr.)
| Period Ended | 31 May 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 31.83 | 28.12 | 20.26 | 13.69 |
| Total Income | 6.21 | 25.61 | 15.84 | 7.19 |
| Profit After Tax | 1.32 | 4.33 | 1.36 | 1.06 |
| EBITDA | 1.93 | 6.16 | 2.55 | 1.52 |
| NET Worth | 12.04 | 10.72 | 6.39 | 1.99 |
| Reserves and Surplus | 5.77 | 4.45 | 5.61 | 1.29 |
| Total Borrowing | 7.83 | 7.26 | 6.82 | 5.25 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹290.00 (-0.60%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹283.00 (-1.57%) |
| Accretion Pharmaceuticals Ltd. | SME | ₹29.75 Cr | ₹101 | 21.29 | ₹82.95 | -17.87% | ₹166.00 (+3.33%) |
| Amwill Health Care Ltd. | SME | ₹59.98 Cr | ₹111 | 13.81 | ₹93.25 | -15.99% | ₹42.11 (+2.71%) |
| Sat Kartar Shopping Ltd. | SME | ₹33.80 Cr | ₹81 | 14.87 | ₹161.55 | +99.44% | ₹130.00 (-1.59%) |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹39.55 (+4.91%) |
| Senores Pharmaceuticals Ltd. | Mainboard | ₹582.11 Cr | ₹391 | 39.77 | ₹557.80 | +42.66% | ₹1,452.90 (-1.74%) |
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,294.90 (+2.45%) |
| Akums Drugs & Pharmaceuticals Ltd. | Mainboard | ₹1,856.74 Cr | ₹679 | null | ₹796.25 | +17.27% | ₹682.95 (-1.22%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit | 6.00 |
| 2 | Funding the incremental working capital requirements of the Company | 13.00 |
| 3 | Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company | 1.00 |
| 4 | General Corporate Purposes | 3.95 |
| 5 | Issue Expenses | 3.61 |
| Total | 27.56 |
About Asston Pharmaceuticals IPO
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally. The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more. The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers. The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing. Products: Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections. Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID). Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Aceta
Contact Details
Asston Pharmaceuticals Ltd. Address4th Floor, Office No.A-431 Balaji BhavanPlot No 42A Sector-11 CBD BelapurThane, Maharashtra, 400614+91 22 49731411info@asstonpharmaceuticals.comVisit Website